Sponsor or institution

Clinical trials and research at Betta Pharmaceuticals Co., Ltd.

• 12Clinical trials
• 2Countries

Newest trials

All recruiting trials (12)

• Befotertinib with Rifampicin or Itraconazole in Healthy People

  This study tests how Befotertinib behaves in the body when taken with rifampicin or itraconazole in healthy volunteers.

  Recruiting Phase 1 Betta Pharmaceuticals Co., Ltd. · Hangzhou, Zhejiang · NCT07809815

• Vorolanib PK study in people with liver impairment

  This study tests how vorolanib behaves in the body after a single dose in people with mild or moderate liver impairment and compares it to people with normal liver function.

  Recruiting Phase 1 Betta Pharmaceuticals Co., Ltd. · Changchun, Jilin · NCT07809802

• Vorolanib Drug-Drug Interaction Test with Rifampicin or Itraconazole

  This study tests how taking vorolanib with rifampicin or itraconazole affects vorolanib levels in healthy adults.

  Recruiting Phase 1 Betta Pharmaceuticals Co., Ltd. · Hangzhou, Zhejiang · NCT07809789

• Icotinib after surgery for early EGFR-mutant NSCLC

  This study tests whether giving icotinib after surgery helps patients with early-stage EGFR-mutant NSCLC compare to just following them after surgery.

  Recruiting at 2 sites Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07806604

• MCLA-129 plus ensartinib for MET‑amplified or MET‑overexpressing advanced solid tumors

  This trial tests whether combining the antibody MCLA-129 with the drug ensartinib helps people with advanced solid tumors that have MET amplification or MET overexpression.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07448116

• BPI-572270 in RAS-mutant advanced solid tumors (including NSCLC, CRC, PDAC)

  This study tests whether BPI-572270 is safe and tolerable in adults with RAS-mutant advanced solid tumors and looks for signs of clinical activity.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Blacktown, New South Wales and 6 other locations · NCT07435038

• Sequential pemetrexed + carboplatin followed by befotertinib for EGFR‑mutant NSCLC after resistance to third‑generation EGFR inhibitors

  This treatment plan will see if giving pemetrexed plus carboplatin followed by the oral drug befotertinib helps people with EGFR‑mutant non‑small cell lung cancer who have stopped responding to third‑generation EGFR inhibitors.

  Recruiting at 2 sites Phase 2 Betta Pharmaceuticals Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07181499

• CFT8919 in advanced EGFR-mutated NSCLC (phase I)

  This early phase study tests CFT8919 capsules to see if they are safe and tolerable and to get a sense of anti-tumor activity in patients with NSCLC driven by EGFR mutations.

  Recruiting Phase 1 Betta Pharmaceuticals Co., Ltd. · Hangzhou, Zhejiang · NCT06641609

• Befotertinib for treating early-stage non-small cell lung cancer with specific mutations

  This study is testing if a new drug called Befotertinib can help people with early-stage non-small cell lung cancer and specific mutations feel better after surgery compared to an existing treatment.

  Recruiting at 3 sites Phase 3 Betta Pharmaceuticals Co., Ltd. · Beijing and 2 other locations · NCT06041776

• Evaluating BPI-460372 for patients with advanced solid tumors

  This study is testing a new drug called BPI-460372 to see if it is safe and effective for people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 4 sites Phase 1 Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT05789602

• Testing a new drug for advanced solid tumors and lymphoma

  This study is testing a new drug called BPI-371153 to see if it is safe and effective for people with advanced solid tumors or lymphoma that hasn’t responded to other treatments.

  Recruiting at 3 sites Phase 1 Betta Pharmaceuticals Co., Ltd. · Chaoyang, Beijing Municipality and 3 other locations · NCT05341557

• MCLA-129 treatment for advanced solid tumors

  This study is testing a new treatment called MCLA-129 for people with advanced solid tumors, like lung or colorectal cancer, to see if it can help them after other treatments haven’t worked.

  Recruiting at 87 sites Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Baoding and 86 other locations · NCT04930432

Quick answers

How many clinical trials run by Betta Pharmaceuticals Co., Ltd. are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (12 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 1/2: 3, Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →